Research information only, not medical advice. CJC-1295 is not FDA-approved. A long-acting growth-hormone-releasing hormone (GHRH) analog studied as a growth-hormone secretagogue, it was removed from the FDA 503A "do not compound" Category 2 in April 2026 (nominations withdrawn) but is not eligible for compounding and remains under Pharmacy Compounding Advisory Committee review. Sold as research only.
CJC-1295 at a glance
As of June 2026 the evidence is limited; early-phase human pharmacology studies report growth-hormone and IGF-1 increases, but most data is preclinical. See the indexed studies below, graded by evidence level.
See also CJC-1295 vs Ipamorelin , Tesamorelin vs CJC-1295 .
Evidence profile
46 studies- Human trial 2 · 4%
- Review 21 · 46%
- Animal 8 · 17%
- In-vitro 8 · 17%
- Unknown 7 · 15%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
- 2026-04-23 US-FDA
Removed from the FDA 503A "do not compound" Category 2 (nominations withdrawn) — still not eligible for compounding; referred to the PCAC. source
Clinical trials
-
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2009Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
An uncontrolled before-and-after study in 11 healthy young adult men found that one week of CJC-1295 administration altered several serum protein levels, suggesting potential biomarkers of GH/IGF-1 action.
- Human trial 2006Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
- Review 2026A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
- Review 2026Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
- Review 2026Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- Review 2026Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
- Review 2026Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Review 2026Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- Review 2016Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions
- Review 2014Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions
This review surveys current analytical methods (chromatographic-mass spectrometric, electrophoretic, and immunological) for detecting peptidic drugs and their analogs in athletes' biological samples and outlines future directions for anti-doping testing.
+ 36 more studies indexed for CJC-1295.
Frequently asked questions
- Is CJC-1295 approved for human use?
- CJC-1295 is not FDA-approved. A long-acting growth-hormone-releasing hormone (GHRH) analog studied as a growth-hormone secretagogue, it was removed from the FDA 503A "do not compound" Category 2 in April 2026 (nominations withdrawn) but is not eligible for compounding and remains under Pharmacy Compounding Advisory Committee review. Sold as research only.
- What does the research on CJC-1295 show?
- As of June 2026 the evidence is limited; early-phase human pharmacology studies report growth-hormone and IGF-1 increases, but most data is preclinical. See the indexed studies below, graded by evidence level.